Yaribeygi Habib, Maleki Mina, Sathyapalan Thozhukat, Rizzo Manfredi, Sahebkar Amirhossein
Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Curr Med Chem. 2024;31(2):138-151. doi: 10.2174/0929867330666230202163513.
Patients with diabetes are at higher risk of cognitive impairment and memory loss than the normal population. Thus, using hypoglycemic agents to improve brain function is important for diabetic patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are a class of therapeutic agents used in the management of diabetes that has some pharmacologic effects enabling them to fight against the onset and progress of memory deficits. Although the exact mediating pathways are not well understood, emerging evidence suggests that SGLT2 inhibition is associated with improved brain function. This study reviewed the possible mechanisms and provided evidence suggesting SGLT2 inhibitors could ameliorate cognitive deficits.
糖尿病患者比正常人群面临更高的认知障碍和记忆力丧失风险。因此，使用降糖药物改善脑功能对糖尿病患者很重要。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）是一类用于糖尿病管理的治疗药物，具有一些药理作用，使其能够对抗记忆缺陷的发生和进展。尽管确切的介导途径尚不完全清楚，但新出现的证据表明，抑制SGLT2与改善脑功能有关。本研究回顾了可能的机制，并提供证据表明SGLT2抑制剂可改善认知缺陷。
